Evaluation of Oncology Treatments: Perceptions from Payer Experts

IPD Analytics has released a new report, “Evaluation of Oncology Treatments: Perceptions from Payer Experts.” Drawing on quantitative surveys completed in June 2026 by payer and health-system experts, IPD's analysts summarize key results and provide actionable insights on high-impact oncology drug launches. The report captures how payers are evaluating new therapies in terms of clinical efficacy, safety, formulary management, and patient access strategies. Key findings reveal that coverage decisions are typically implemented within 6 months of FDA approval, and drugs priced 25% or more above the standard of care are more likely to face restrictive management.

IPD’s Primary Market Insights provide a window into the dynamic market pulse of rapidly evolving competitive landscapes and disease areas. Subscribers can access additional up-to-date information through the IPD Analytics platform.

Content on this site is proprietary to IPD Analytics. This sample is not for distribution. By receiving it, you agree to refrain from any unauthorized use, including uploading or inputting it into AI tools or large language models (LLMs) for training or any other purpose. This is strictly prohibited.